Literature DB >> 24955986

Association between tuberculosis recurrence and interferon-γ response during treatment.

Nguyen Thi Le Hang1, Ikumi Matsushita2, Takuro Shimbo3, Le Thi Hong4, Do Bang Tam4, Luu Thi Lien5, Pham Huu Thuong6, Vu Cao Cuong6, Minako Hijikata7, Nobuyuki Kobayashi8, Shinsaku Sakurada9, Kazue Higuchi10, Nobuyuki Harada10, Hiroyoshi Endo11, Naoto Keicho12.   

Abstract

OBJECTIVES: We investigated the relationship between tuberculosis recurrence and Mycobacterium tuberculosis antigen-stimulated interferon-gamma (IFN-γ) responses during treatment.
METHODS: Plasma IFN-γ levels in active pulmonary tuberculosis patients (n = 407) were analyzed using QuantiFERON-TB Gold In-Tube™ (QFT-IT) at 0, 2, and 7 months of the 8-month treatment received from 2007 to 2009 and the patients were followed up for another 16 months after treatment. Risk factors for recurrence were assessed using the log-rank test and Cox proportional hazard models. Random coefficient models were used to compare longitudinal patterns of IFN-γ levels between groups.
RESULTS: QFT-IT showed positive results in 95.6%, 86.2%, and 83.5% at 0, 2, and 7 months, respectively. The antigen-stimulated IFN-γ responses varied significantly during the treatment course (P < 0.0001). Unexpectedly, positive-to-negative conversion of QFT-IT results between 0 and 2 months was significantly associated with earlier recurrence (adjusted hazard ratio, 5.57; 95% confidence interval, 2.28-13.57). Time-dependent changes in IFN-γ levels were significantly different between the recurrence and nonrecurrence groups (P < 0.0001).
CONCLUSIONS: Although the IGRA response varies individually, early response during the treatment course may provide an insight into host immune responses underlying tuberculosis recurrence.
Copyright © 2014 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cellular response; Interferon-γ release assay; Recurrence; Tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24955986     DOI: 10.1016/j.jinf.2014.06.007

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

1.  Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters.

Authors:  S E Medellín-Garibay; N Cortez-Espinosa; R C Milán-Segovia; M Magaña-Aquino; J M Vargas-Morales; R González-Amaro; D P Portales-Pérez; S Romano-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

2.  Performance Evaluation of a New Automated Chemiluminescent Immunoanalyzer-Based Interferon-Gamma Releasing Assay AdvanSure I3 in Comparison With the QuantiFERON-TB Gold In-Tube Assay.

Authors:  Jin Ju Kim; Younhee Park; Dasom Choi; Hyon Suk Kim
Journal:  Ann Lab Med       Date:  2020-01       Impact factor: 3.464

3.  Serial anti-tuberculous immune responses during the follow-up of patients with tuberculous pleurisy.

Authors:  Bing-Yan Zhang; Zhi-Min Yu; Qing-Luan Yang; Qian-Qian Liu; Hua-Xin Chen; Jing Wu; Sen Wang; Ling-Yun Shao; Xin-Hua Weng; Qin-Fang Ou; Yan Gao; Wen-Hong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.